Ovarian cancer (OVCA), particularly the aggressive high-grade serous ovarian cancer (HGSOC), represents a major challenge in women’s health worldwide. Understanding the expression levels of key biomarkers in human ovarian cancer tissues is important for the development of next-generation antibody-drug conjugates (ADCs) for cancer treatment.
